Eton Pharmaceuticals delivered impressive second-quarter results, with total net revenues reaching $18.9 million, a 108% increase year-over-year, primarily fueled by strong product sales of ALKINDI SPRINKLE, INCRELEX, and GALZIN. The company achieved non-GAAP diluted EPS of $0.03 and significantly improved its Adjusted EBITDA to $3.1 million. Key operational successes included the FDA approval and launch of KHINDIVI, reaching 100 active INCRELEX patients ahead of schedule, and advancing its pipeline programs.

Eton Pharmaceuticals delivered a standout Q1 2025, driven by 76% growth in product sales and newly added licensing revenue. Despite a net loss on a GAAP basis, the company posted positive non-GAAP earnings and expects continued growth from product launches and development milestones.

Eton Pharmaceuticals delivered its strongest quarter yet in Q4 2024 with record net revenues of $11.6 million, driven by significant growth in ALKINDI SPRINKLE and Carglumic Acid. Gross profit increased to $6.5 million, while the company reported a net loss of $0.6 million due to strategic investments and transaction costs.

Eton Pharmaceuticals reported a strong third quarter with product sales reaching $9.8 million, a 40% increase year-over-year. The company achieved positive GAAP net income from product revenue for the first time. They also entered an agreement to acquire Increlex and had their NDA for ET-400 accepted by the FDA.

Eton Pharmaceuticals reported a net loss of $2.9 million, which includes a $2.0 million ET-400 filing fee. However, the company saw a 40% increase in product sales and royalty revenue compared to Q2 2023, reaching $9.1 million, driven by ALKINDI SPRINKLE and Carglumic Acid. The FDA accepted the NDA for ET-400 with a PDUFA date of February 28, 2025. The company generated $1.3 million in operating cash flow, including the payment of the one-time $2.0 million NDA filing fee for ET-400.

Eton Pharmaceuticals reported a strong start to 2024, marked by record product sales, a 50% revenue increase compared to Q1 2023, and the acquisition of PKU GOLIKE. The company also launched Nitisinone and submitted an NDA for ET-400.

Eton Pharmaceuticals reported a strong fourth quarter, marked by a 109% increase in product sales and royalty revenue. The company achieved positive operating cash flow and saw favorable developments in its pipeline, including positive study results for ET-400 and ET-600.

Eton Pharmaceuticals reported a net revenue of $7.0 million, a 118% increase compared to the prior year period. The company achieved positive cash flow from operations and ended the quarter with $22.1 million in cash on hand. They also acquired Nitisinone Capsules, an ultra-rare disease product.

Eton Pharmaceuticals reported a strong second quarter with record product sales and royalty revenue of $6.5 million, a 175% increase year-over-year. The company achieved profitability, driven by growth in ALKINDI SPRINKLE and Carglumic Acid, and increased its full-year revenue expectation to approximately $30 million.

Eton Pharmaceuticals reported a strong first quarter, driven by record sales of ALKINDI SPRINKLE® and Carglumic Acid, which were boosted by an expanded sales force. The company also launched Betaine Anhydrous and acquired ET-600, a rare disease product candidate. Eton is approaching profitability with a solid cash position.

Eton Pharmaceuticals reported a strong fourth quarter, marked by a 220% increase in product sales and royalty revenue compared to the prior year, driven by ALKINDI SPRINKLE and Carglumic Acid. The company is optimistic about future growth, expecting to at least double product sales and royalty revenue in 2023.

Eton Pharmaceuticals reported a 315% increase in product sales and royalties compared to the prior year, driven by growth in ALKINDI SPRINKLE and Carglumic Acid. The company also acquired Betaine Anhydrous and received FDA approval for Zonisade™.

Eton Pharmaceuticals reported a net sales increase to $7.4 million, driven by licensing payments and growth in ALKINDI SPRINKLE and Carglumic Acid tablets. The company is now focused on its rare disease strategy following the hospital products divestiture.

Eton Pharmaceuticals reported a net loss of $5.3 million for the first quarter of 2022, with product sales and royalty revenue of $2.2 million. The company is experiencing growth in ALKINDI SPRINKLE® and the launch of carglumic acid and Rezipres®.

Eton Pharmaceuticals reported a profitable fourth quarter with a net income of $1.0 million, a significant improvement compared to the previous year's net loss. Revenue reached $6.1 million, boosted by a milestone payment. The company launched carglumic acid, saw accelerated growth of ALKINDI SPRINKLE through a co-promotion partnership, and launched Rezipres.

Eton Pharmaceuticals reported third quarter financial results with revenue of $0.8 million and a net loss of $6.1 million. The company made advancements to its commercial portfolio with two more FDA-approved products and is increasing ALKINDI SPRINKLE’s commercial footprint.

Eton Pharmaceuticals reported revenue of $3.1 million for the second quarter of 2021, which included $2.5 million of licensing revenue. The company also reported a net loss of $2.0 million, with an EPS of ($0.08).

Eton Pharmaceuticals reported a record revenue of $11.9 million and its first profitable quarter with an operating income of $5.4 million. The company's success is attributed to three revenue-generating products and payments from the sale of neurology oral liquids products.

Eton Pharmaceuticals reported $0.1 million in revenue for Q4 2020, with a net loss of $7.7 million. The company launched ALKINDI SPRINKLE late in the quarter, and its impact on revenue was minimal. The company is focusing on achieving profitability by the end of 2021.

Eton Pharmaceuticals reported revenue of $20,000 in the second quarter of 2020, primarily from Biorphen sales. The company's net loss for the quarter was $4.7 million, and they had cash and cash equivalents of $10.3 million as of June 30, 2020.

Eton Pharmaceuticals reported first quarter results with revenue of $0.1 million, impacted by the COVID-19 pandemic, and a net loss of $9.0 million. The company acquired marketing rights to Alkindi Sprinkle and strengthened its balance sheet with $9.8 million of additional liquidity.

Eton Pharmaceuticals reported revenue of $0.5 million for the fourth quarter of 2019, driven by initial Biorphen stocking orders. The company's net loss for the quarter was $2.7 million. As of December 31, 2019, Eton had cash and cash equivalents of $12.1 million.